We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
- Authors
Gatanaga, Hiroyuki; Hayashida, Tsunefusa; Tsuchiya, Kiyoto; Yoshino, Munehiro; Kuwahara, Takeshi; Tsukada, Hiroki; Fujimoto, Katsuya; Sato, Isao; Ueda, Mikio; Horiba, Masahide; Hamaguchi, Motohiro; Yamamoto, Masahiro; Takata, Noboru; Kimura, Akiro; Koike, Takao; Gejyo, Fumitake; Matsushita, Shuzo; Shirasaka, Takuma; Kimura, Satoshi; Oka, Shinichi
- Abstract
Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6), and high plasma concentrations of the drug are associated with a G-->T polymorphism at position 516 (516G-->T) of CYP2B6 and frequent central nervous system (CNS)-related side effects. Here, we tested the feasibility of genotype-based dose reduction of EFV.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Vol 45, Issue 9, p1230
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/522175